To optimize the management of patients with long-term remission of metastatic HER2-positive disease beyond the STOP-HER2 trial, several strategies can be considered:
Regular Monitoring: Implementing a structured surveillance plan with regular imaging and clinical assessments to detect any signs of disease recurrence early.
Personalized Treatment: Utilizing precision medicine approaches to tailor therapy based on individual patient characteristics, including genetic profiles, treatment response, and potential risk factors for recurrence.
Shared Decision-Making: Engaging patients in shared decision-making to discuss the risks and benefits of continuing HER2-targeted therapy versus stopping treatment after a prolonged period of remission.
Exploring Treatment Holidays: Considering intermittent treatment schedules or treatment holidays for patients with long-term remission to minimize potential toxicities while maintaining disease control.
Incorporating Novel Therapies: Evaluating the role of emerging therapies, such as new HER2-targeted agents or immunotherapies, in maintaining long-term remission and preventing disease recurrence.
By adopting a comprehensive and patient-centered approach that combines regular monitoring, personalized treatment strategies, shared decision-making, treatment holidays, and exploration of novel therapies, the management of patients with long-term remission of metastatic HER2-positive disease can be further optimized to ensure optimal outcomes and quality of life.